Influence of DESTINY-PanTumor02 Trials on Trastuzumab Deruxtecan Usage

Patients with driver gene–negative non–small cell lung cancer who received immunotherapy beyond progression experienced better survival outcomes.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.

"Anything that you can do to leverage technology to minimize the variability in surgery eliminates the skill gap so that novice surgeons may become as technically gifted as the intermediate surgeon or the master surgeon."